Sponsors
The bill strengthens domestic medical and defense supply-chain resilience and oversight through federal planning and targeted payments, but does so at the risk of higher costs to taxpayers and patients, expanded federal intervention in private contracts, and potential market distortions that could disadvantage smaller competitors and slow innovation.
Hospitals and patients dependent on drugs, devices, and biologics would face clearer federal planning and coordination that reduces the risk of supply shortages during national emergencies.
U.S. manufacturers and suppliers (including smaller firms) would be eligible for federal payments to strengthen domestic production and supply chains, lowering reliance on foreign sources for defense-critical goods and improving resilience.
Congress and state governments would receive a required national strategy and annual progress reports through 2029, improving transparency, oversight, and accountability of federal supply-chain actions.
Taxpayers and patients could face higher costs because securing supply chains and subsidizing domestic production may raise production costs and lead to higher prices or new federal expenditures without specified limits.
Hospitals, suppliers, and private contractors could see disruptions to existing commercial contracts and increased federal intervention as broad authorities (e.g., DPA-style actions or procurement controls) are used to redirect production.
Patients and the innovation ecosystem risk reduced competition and slower innovation if mitigation measures like reshoring incentives or exclusivity limits are implemented in ways that favor incumbents or constrain market entry.
Based on analysis of 3 sections of legislative text.
Requires a DPA-based strategy to secure medical supply chains and authorizes presidential payments to U.S. entities to strengthen those chains, with set deadlines and reporting.
Introduced March 3, 2026 by Maria Elvira Salazar · Last progress March 3, 2026
Requires the President to write and deliver a national strategy that uses Defense Production Act authorities (and other law) to secure U.S. medical supply chains and supply of drugs, devices, and biological products. It also authorizes the President to make payments to U.S.-organized entities to strengthen those supply chains, sets short regulatory and reporting deadlines, and allows classified annexes for sensitive materials. The law sets a 180‑day deadline for the administration to transmit the strategy to Congress, a 90‑day deadline to define key terms by regulation, annual progress reports through 2029, and a 30‑day Congressional notice requirement before making payments deemed critical for national defense.